Orbimed Advisors Lowered Its Alexion Pharmaceuticals (Call) (ALXN) Holding; Cohen & Steers MLP Income & Energy Opportunity Fund (MIE) Sentiment Is 1.7

June 20, 2017 - By Maria Brooks

Cohen & Steers MLP Income and Energy Opportunity Fund, Inc. is a non-diversified, closed-end management investment company. The company has market cap of $284.01 million. The Fund’s investment objective is to provide attractive total return, consisted of high current income and price appreciation. It currently has negative earnings. Under normal market conditions, the Fund will invest at least 80% of its managed assets in energy-related master limited partnerships (MLPs) and companies that are involved in the exploration, production, gathering, transportation, processing, storage, refining, distribution or marketing of natural gas, natural gas liquids (including propane), crude oil, refined petroleum products, coal or other energy sources (related companies).

Orbimed Advisors Llc decreased Alexion Pharmaceuticals Inc (Call) (ALXN) stake by 96.21% reported in 2016Q4 SEC filing. Orbimed Advisors Llc sold 2.54 million shares as Alexion Pharmaceuticals Inc (Call) (ALXN)’s stock declined 11.63%. The Orbimed Advisors Llc holds 100,000 shares with $12.24M value, down from 2.64M last quarter. Alexion Pharmaceuticals Inc (Call) now has $27.39B valuation. The stock rose 3.03% or $3.52 reaching $119.68. About 2.40M shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since June 20, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

About 112,372 shares traded or 3.80% up from the average. Cohen & Strs MLP Inc & Ergy Oprty Fd Inc (MIE) has risen 16.72% since June 20, 2016 and is uptrending. It has outperformed by 0.02% the S&P500.

Thomas J. Herzfeld Advisors Inc. holds 0.55% of its portfolio in Cohen & Strs MLP Inc & Ergy Oprty Fd Inc for 108,534 shares. Sit Investment Associates Inc owns 1.41 million shares or 0.4% of their US portfolio. Moreover, Advisors Asset Management Inc. has 0.15% invested in the company for 806,996 shares. The United Kingdom-based City Of London Investment Management Co Ltd has invested 0.1% in the stock. Salient Capital Advisors Llc, a Texas-based fund reported 224,577 shares.

Orbimed Advisors Llc increased Aetna Inc New (NYSE:AET) stake by 689,300 shares to 805,900 valued at $99.94M in 2016Q4. It also upped Allergan Plc stake by 719,690 shares and now owns 769,690 shares. Tenet Healthcare Corp (NYSE:THC) was raised too.

Investors sentiment is 1.07 in Q4 2016. Its the same as in 2016Q3. It is the same, as 59 investors sold ALXN shares while 167 reduced holdings. only 81 funds opened positions while 160 raised stakes. 215.83 million shares or 2.26% more from 211.05 million shares in 2016Q3 were reported. Gam Ag has 0.18% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Greenwood Assoc Ltd Limited Liability Company holds 0.06% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 1,653 shares. Moreover, Advisors Asset has 0.04% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 17,462 shares. Blackrock Japan Limited holds 299,847 shares or 0.12% of its portfolio. Mirae Asset Investments Com Limited accumulated 16,937 shares or 0.05% of the stock. Janney Montgomery Scott Ltd Llc invested 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Invesco Ltd holds 0.15% or 3.70M shares. Mackenzie Fincl Corporation accumulated 39,900 shares. Rhumbline Advisers owns 376,594 shares. Kingdon Cap Management owns 45,000 shares or 0.27% of their US portfolio. Aberdeen Asset Management Public Ltd Com Uk invested in 39,085 shares. State Street Corp holds 0.12% or 10.58 million shares in its portfolio. Cornerstone Mngmt Holding invested 0.04% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Calamos Advsr Ltd Liability has 21,082 shares. Blackrock Mngmt Ltd owns 2.31 million shares or 0.33% of their US portfolio.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on July, 27. They expect $1.10 earnings per share, up 18.28% or $0.17 from last year’s $0.93 per share. ALXN’s profit will be $251.75 million for 27.20 P/E if the $1.10 EPS becomes a reality. After $1.20 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.33% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: